Pharmacokinetic Measurements in Dose Finding Model Guided by Escalation with Overdose Control

2024/04/17 by Maity, Arnab Kumar, Chowdhury, Satrajit Roy, Li, Ray +2
#Applications (stat.AP) #Computation (stat.CO) #FOS: Computer and information sciences

paper · doi:10.48550/arxiv.2404.11406

Abstract

Oncology drug development starts with a dose escalation phase to find the maximal tolerable dose (MTD). Dose limiting toxicity (DLT) is the primary endpoint for dose escalation phase. Traditionally, model-based dose escalation trial designs recommend a dose for escalation based on an assumed dose-DLT relationship. Pharmacokinetic (PK) data are often available but are currently only used by clinical teams in a subjective manner to aid decision making. Formal incorporation of PK data in dose-escalation models can make the decision process more efficient and lead to an increase in precision. In this talk we present a Bayesian joint modeling framework for incorporating PK data in Oncology dose escalation trials. This framework explores the dose-PK and PK-DLT relationships jointly for better model informed dose escalation decisions. Utility of the proposed model is demonstrated through a real-life case study along with simulation.

Related

• Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
• U-DESPE: a Bayesian Utility-based methodology for dosing regimen optimization in early-phase oncology trials based on Dose-Exposure, Safety, Pharmacodynamics, Efficacy
• Bayesian model for early dose-finding in phase I trials with multiple treatment courses
• Improving the Performance of Bayesian Logistic Regression Model with Overdose Control in Oncology Dose-Finding Studies
• A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages